Targeting STING oligomerization with small-molecule inhibitors

Fiachra Humphries,Liraz Shmuel-Galia,Zhaozhao Jiang,Jeffrey Y Zhou,Leonard Barasa,Santanu Mondal,Ruth Wilson,Nadia Sultana,Scott A Shaffer,Sze-Ling Ng,G Scott Pesiridis,Paul R Thompson,Katherine A Fitzgerald,Jeffrey Y. Zhou,Scott A. Shaffer,G. Scott Pesiridis,Paul R. Thompson,Katherine A. Fitzgerald

DOI: https://doi.org/10.1073/pnas.2305420120

2023-08-09

Abstract:Stimulator of interferon genes (STING) is an essential adaptor protein required for the inflammatory response to cytosolic DNA. dsDNA activates cGAS to generate cGAMP, which binds and activates STING triggering a conformational change, oligomerization, and the IRF3- and NFκB-dependent transcription of type I Interferons (IFNs) and inflammatory cytokines, as well as the activation of autophagy. Aberrant activation of STING is now linked to a growing number of both rare as well as common chronic inflammatory diseases. Here, we identify and characterize a potent small-molecule inhibitor of STING. This compound, BB-Cl-amidine inhibits STING signaling and production of type I IFNs, IFN-stimulated genes (ISGs) and NFκB-dependent cytokines, but not other pattern recognition receptors. In vivo, BB-Cl-amidine alleviated pathology resulting from accrual of cytosolic DNA in Trex-1 mutant mice. Mechanistically BB-Cl-amidine inhibited STING oligomerization through modification of Cys 148 . Collectively, our work uncovers an approach to inhibit STING activation and highlights the potential of this strategy for the treatment of STING-driven inflammatory diseases.